BUSINESS
Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
By Ken Yoshino November 18, 2026
Combined revenue at 23 major Japanese pharmaceutical companies surged 14.7% year-on-year to 9.17 trillion yen in the first half of FY2026, buoyed largely by a weaker yen that lifted overseas sales, according to a Jiho…

LATEST

November 18, 2026
Japan’s two largest pure-play generic makers both delivered higher sales and operating profits in April-September, lifted by expanded production capacities. Elsewhere in the sector, authorized generics (AGs) and biosimilars continued to drive growth, although drug…
November 18, 2026
Kyowa Kirin plans to discontinue sales of its diabetes drug Onglyza (saxagliptin) in November 2027, marking the first announced sales termination of an originator DPP-4 inhibitor in Japan as generic competition reshapes the market.The company…
November 18, 2026
Eisai said on November 17 that five years of continuous treatment with Leqembi (lecanemab) helped patients with early Alzheimer’s disease (AD) remain in the earlier stages of the disease longer, with benefits continuing to build…

Japan’s health ministry on November 16 approved AbbVie’s glabellar lines drug Boey (trenibotulinumtoxinE), along with a slate of label expansions…

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

By Shunsuke Tani

Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA